Rationale and design of the phase 3a development programme ( ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes

The ONWARDS 1-6 trials will evaluate the efficacy and safety of once-weekly icodec compared with currently available daily basal insulin analogues in T2D and T1D. These trials will generate comprehensive evidence of icodec use in diverse populations across the spectrum of diabetes progression and treatment experience.